Sitravatinib/MGCD516 (Mirati Therapeutics) is a multitargeted kinase inhibitor that potently enhances the efficacy of anti-PD-1, as observed in the murine KLN205 lung- as well as in the murine E0771 breast- cancer models (216). The gene discussed is PDCD1; the disease is breast carcinoma.